Analysis
AEON Biopharma filed an S-1 registration statement with the SEC on July 8 covering a biosimilar development program, under which the company holds exclusive rights to develop and commercialize ABP-450 across the US, Canada, the EU, UK and other territories. A day later, Mobix Labs filed an amended S-1/A registering roughly 3.7 million shares of Class A common stock for resale by existing stockholders -- shares tied to debt settlements, a litigation settlement, an earnout, and newly issued Series A 10% convertible preferred stock.
The Mobix filing is the more sobering of the two: the company disclosed operating losses of $37.7 million and $46.4 million across its last two fiscal years, an accumulated deficit of $166.6 million as of March 2026, and management's own statement that there is "substantial doubt" about the company's ability to continue as a going concern. That's about as far from SK Hynix's 7x-oversubscribed book or Anthropic's $50 billion private round as the public markets get -- a small-cap company registering dilutive resale shares just to manage its balance sheet.
Both filings sit alongside a broader wave of smaller S-1 and S-1/A activity moving through the SEC this week, including SPAC vehicles Southern Cross Acquisition II Corp and OceanLight Acquisition Corp, both Cayman Islands-incorporated blank-check companies that filed or amended registration statements in the same stretch of days. None of this pipeline resembles the large-cap tech reopening some bankers predicted would follow SpaceX's record-breaking June IPO.
“None of this pipeline resembles the large-cap tech reopening some bankers predicted would follow SpaceX's record-breaking June IPO.”
The gap between this week's AI mega-deals -- Mercor's reported $20 billion valuation talks, Anthropic's $50 billion round, Blue Origin's $10 billion raise -- and AEON's and Mobix's far more modest, dilution-driven filings captures the real shape of 2026's capital markets: extraordinary abundance at the very top of the market, concentrated in AI infrastructure and foundation labs, alongside ordinary or even distressed conditions for smaller public and pre-public companies with no AI-infrastructure story to tell.
For founders and management teams at smaller public or soon-to-be-public companies, the Mobix disclosure is a useful reminder that going-concern language and dilutive resale registrations remain a live risk in 2026's markets even as headline AI valuations soar -- the rising tide is not lifting every boat. For investors scanning the S-1 pipeline for signal, the practical filter right now is simple: does the filer have a credible AI-infrastructure or foundation-model story, or is it competing for capital in the far more competitive, far less generous market everyone else operates in.
The bear case for reading too much into either filing: individual small-cap biotech and hardware companies navigating dilution and going-concern disclosures are a normal, constant feature of public markets in any environment, not a unique signal about 2026 specifically. What to watch next: whether AEON's S-1 proceeds to pricing and how the market receives it, and whether Mobix Labs' going-concern language triggers any Nasdaq listing-compliance scrutiny in the coming months.
